Clinical Use and Perception About Synthetic Liothyronine for the Treatment of Primary Hypothyroidism Among Healthcare Professionals in India Authors: Sameer Aggarwal, Lovely Gupta, Deepak Khandelwal, Sachin Chittawar, Shweta Sharma, Mohan T. Shenoy, Umesh K. Garg, Naima Parveen, Mona Sood Published: 2026 ABSTRACT Introduction:Hypothyroidism is commonly managed with levothyroxine (LT4) monotherapy, the standard treatment for many decades. However, 5%–10% of patients remain symptomatic despite achieving biochemical euthyroidism on LT4 monotherapy. Liothyronine (LT3), a synthetic form of T3, was introduced in India in 2022 but faces limited adoption due to availability, cost, and lack of clear guidelines. This study aimed to assess the perceptions, clinical usage, and barriers to LT3 prescription among healthcare professionals in India.Methods:A cross-sectional, questionnaire-based study was conducted among 455 doctors attending three endocrinology updates in Delhi, Bhopal, and Rohtak. The participants completed a 19-question structured online survey assessing demographics, LT3 awareness, usage patterns, and barriers. The responses were analysed using SPSS version 20.Results:Out of 455 respondents (42.15 ± 11.41 years), 80% were males and 27.69% were endocrinologists. LT3 awareness was reported by 80%, with 52.75% reported prescribed it, most commonly for hypothyroid emergencies (40.42%), rapid symptom control (22.50%), or persistent symptoms despite biochemical euthyroidism on LT4 monotherapy (17.50%). However, the major barriers included high cost (23.52%) and limited availability (22.86%). Among prescribers, 62.08% used once-daily dosing. Also, 74.29% of participants expressed interest in further learning about LT3.Conclusion:Reported use of LT3 in India remains limited, driven by poor awareness among clinicians, cost, and availability issues. Although awareness is high among specialists, consistent guidelines, clinician education, and accessibility improvements are needed for safe and effective LT3 integration into hypothyroidism management. INTRODUCTION Thyroid dysfunction refers to abnormality in the thyroid gland’s structure or function and is commonly associated with metabolic disorders despite limited screening guidelines.[1] Hypothyroidism, a prevalent endocrine disorder, is typically treated with thyroid hormone replacement. Desiccated thyroid containing both thyroxine (T4) and liothyronine (LT3) was used until the 1970s but is no longer preferred due to purity issues and high T3 content. Since T4 is converted to triiodothyronine (T3) in peripheral tissues, synthetic levothyroxine (LT4) has been the standard treatment to normalize symptoms and maintain TSH levels from the American Association of Clinical Endocrinologists, the American Thyroid Association, and The Endocrine Society.[234] The combination LT4 and LT3 therapy is considered for a small group of patients who remain symptomatic despite normal TSH levels. Up to 5%–10% of such patients may benefit, though other causes of persistent symptoms should be evaluated first.[56] LT3 may help in selected cases, particularly with D2 gene polymorphism. It is typically used in a LT4/LT3 ratio of 13:1 to 20:1, though the evidence is limited.[57] LT3 monotherapy can restore euthyroidism but is rarely used.[47] Although some studies suggest improved quality of life with LT4 + LT3 in select patients, long-term safety remains a concern.[8910] LT3 was approved by the FDA in 1956 but was recently introduced in India by Abbott under the brand LINORMA-T3 in 2022.[11] Despite sales of over 4000 bottles by December 2024, its availability remains limited due to cost and supply issues.[12] This study explores LT3 prescription practices and clinician perceptions in India. MATERIALS AND METHODS Study design and setting This was a questionnaire-based cross-sectional study conducted during three Endocrine Update CMEs held in Delhi, Bhopal (Madhya Pradesh), and Rohtak (Haryana), attended by over 800 doctors from various specialties. The participating doctors received an online questionnaire link at the beginning of the events. The questionnaire consisted of 19 multiple-choice questions, each allowing only one preferred response, and was designed to assess treatment practices and preferences regarding LT3 use in hypothyroidism. Based on a pilot study involving 15 doctors, 10 min were allotted to complete the form. The submission required responses to all questions, ensuring 100% completion. To maintain confidentiality and reduce bias, email IDs were blinded and no personal information was collected. Data collection tools A Google form consisting of a structured questionnaire assessing LT3 usage, perception, prescribing behaviour, and identification of key barriers influencing LT3 use in clinical practice was assessed. Questionnaire The questions 1–5 were related to basic characteristics of the participants like age, gender, speciality, years of clinical practice and set-up as well as place for their clinical practice. Questions 6–8 assessed the approximate number of new as well as follow-up cases of primary hypothyroid patients seen on a monthly basis, and an approximate number of symptomatic patients they feel remain symptomatic in spite of normal TSH and LT4 treatment. The questions 9–12 were related to the awareness and ease of its availability of oral synthetic LT3, its usage, number of patients among whom LT3 has been used, and the most commonly prescribed frequency of its administration in their clinical practice. The questions 13–17 evaluated the reasons and barriers for prescribing and non-prescribing the LT3. The questions 18 and 19 evaluated the participant’s preference to learn more regarding LT3 from experts for more confidence in the clinical practice and the best medium that they would like to learn about LT3. The detailed questionnaire has been elaborated at the end of the manuscript. Eligibility Study participants were a diverse group of practising doctors ranging from family physicians/general practitioners, obstetricians, internal medicine specialists, surgeons, and endocrinologists practising in India, who voluntarily chose to attend the CME and were ready to fill the questionnaire. The venue, timing, and the programme content of the CME were advertised in the form of visual material and posters using social media as well as physical posters for the prior month to the actual event. Healthcare professionals who attended the CME but not primarily involved in diagnosing, prescribing, and treating the patients of primary hypothyroidism as well as non-willing participants were excluded. Sampling method The study used a mixed sampling approach, combining purposive and convenience sampling. Purposive sampling targeted the practitioners while convenience sampling selected easily accessible participants, expanding the sample size and encompassing a broader representation across specialties and regions. Data analysis Summary statistics were prepared for responses to each question. Answering all the questions was mandatory. The analysis was performed using the Statistical Package for the Social Sciences (SPSS) (Chicago, Illinois, USA) version-18 software. Ethical aspects As this was a questionnaire-based study of practising doctors about their perception and clinical practice, ethics committee approval is not required for this study. Also, no direct patients were involved in this study; hence, consent is not relevant for this study. RESULTS More than 800 doctors participated in the CME programme, of which 455 doctors filled the questionnaire. The mean age of the participating doctors was 42.15 ± 11.41 years. Most of the participants were males (367 [80.66%]). The participants varied by their speciality, with 126 (27.69%) being endocrinologists, 258 (56.70%) physicians, 11 (2.42%) gynaecologists, 22 (4.84%) general practitioners, and 38 (8.35%) from other specialities. Regarding their clinical practice, 30.55% had less than 5 years of experience in clinical practice and 26.81% had between 5 and 10 years of experience in clinical practice [Table 1]. A majority of practitioners reported working in either district (42.64%), followed by in metro cities or state capitals (40.00%). The most common reported setting of clinical practice was working in private hospitals (31.65%), followed by working in medical colleges (27.47%). Table 1Demographic and clinical practice-related information about the doctors who participated in the study (n=455)ParametersMean±SD or n (%)Age (years)42.15±11.41Gender Male367 (80.66%) Female88 (19.34%)Speciality Endocrinologists126 (27.69%) Physicians258 (56.70%) Gynaecologists11 (2.42%) General practitioners22 (4.84%) Others38 (8.35%)Total years of clinical practice <5 years139 (30.55%) 5–10 years122 (26.81%) 10–15 years60 (13.19%) 15–20 years47 (10.33%) >20 years87 (19.12%)Place that best defines the primary practice area Metro cities/State capital182 (40.00%) District194 (42.64%) Town71 (15.60%) Village8 (1.76%)Set-up that best defines the clinical practice Medical college125 (27.47%) Government hospital (without medical college)46 (10.11%) Private hospital144 (31.65%) Only clinic based59 (12.97%) Both hospital + clinic-based81 (17.80%) Demographic and clinical practice-related information about the doctors who participated in the study (n=455) Table 2 summarizes hypothyroid management practices among respondent doctors. Regarding the number of new hypothyroid patients seen monthly, the majority (175 doctors, 38.46%) reported seeing 10–30 new patients, followed by 126 (27.69%) seeing 5–10. A total of 112 doctors (24.62%) managed more than 30 new cases monthly. Among endocrinologists, nearly half (61, 48.41%) saw over 30 new patients monthly, and 47 (37.30%) saw 10–30. Among physicians, 114 (44.19%) saw 10–30 new cases, and 83 (32.17%) saw 5–10. Most gynaecologists (5, 45.45%) reported 5–10 new cases per month, while general practitioners were more varied, 8 (36.36%) saw 5–10 and 7 (31.82%) saw fewer than 5. For monthly follow-up patients, the largest group (162 doctors, 35.60%) managed 10–50, followed by 121 (26.59%) who saw fewer than 10. Another 80 (17.58%) handled 50–100, while 52 (11.43%) managed 100–300, and 40 (8.79%) saw more than 300. Endocrinologists had a heavier follow-up load—32 (25.40%) managed over 300, and 31 (24.60%) managed 100–300. Physicians primarily managed 10–50 follow-up patients (104, 40.31%), and 82 (31.78%) saw fewer than 10. Most gynaecologists (6, 54.55%) reported 10–50 follow-ups, while general practitioners mostly managed fewer than 10 (13, 59.09%). In the ‘others’ category, 16 doctors each (42.11%) managed fewer than 10 or 10–50 follow-up patients. Regarding the proportion of hypothyroid patients with normal TSH but persistent symptoms despite LT4 therapy, 198 doctors (43.52%) believed fewer than 5% were affected. Another 158 (34.73%) estimated 5%–10%, 72 (15.82%) estimated 10%–20%, and 27 (5.93%) reported more than 20%. Among endocrinologists, 48 (38.10%) reported <5%, 42 (33.33%) reported 5%–10%, and 11 (8.73%) reported >20%. Among physicians, 112 (43.41%) estimated <5%, and 94 (36.43%) estimated 5%–10%, while 12 (4.65%) observed symptoms in over 20% of patients. Table 2Information pertaining to hypothyroid practices for doctors who participated in the studyTotal participants n=455Endocrinologists n=126Physicians n=258Gynaecologists n=11General practitioners n=22Others n=38Approx. number of new hypothyroid patients seen in a month <542 (9.23%)1 (0.79%)20 (7.75%)1 (9.09%)7 (31.82%)13 (34.21%) 5–10126 (27.69%)17 (13.49%)83 (32.17%)5 (45.45%)8 (36.36%)13 (34.21%) 10–30175 (38.46%)47 (37.30%)114 (44.19%)3 (27.27%)3 (13.64%)8 (21.05%) >30112 (24.62%)61 (48.41%)41 (15.89%)2 (18.18%)4 (18.18%)4 (10.53%)Approx. number of follow-up hypothyroid patients seen in a month <10121 (26.59%)6 (4.76%)82 (31.78%)4 (36.36%)13 (59.09%)16 (42.11%) 10–50162 (35.60%)29 (23.02%)104 (40.31%)6 (54.55%)7 (31.82%)16 (42.11%) 50–10080 (17.58%)28 (22.22%)48 (18.60%)1 (9.09%)1 (4.55%)2 (5.26%) 100–30052 (11.43%)31 (24.60%)18 (6.98%)-1 (4.55%)2 (5.26%) >30040 (8.79%)32 (25.40%)6 (2.33%)--2 (5.26%)Approx. % of hypothyroid patients on LT4 with normal TSH and persistent hypothyroid symptoms <5%198 (43.52%)48 (38.10%)112 (43.41%)5 (45.45%)13 (59.09%)20 (52.63%) 5%–10%158 (34.73%)42 (33.33%)94 (36.43%)6 (54.55%)5 (22.73%)11 (28.95%) 10%–20%72 (15.82%)25 (19.84%)40 (15.50%)-3 (13.64%)4 (10.53%) >20%27 (5.93%)11 (8.73%)12 (4.65%)-1 (4.55%)3 (7.89%)*LT4=Levothyroxine, TSH=Thyroid stimulating hormone. *n (%) Information pertaining to hypothyroid practices for doctors who participated in the study *LT4=Levothyroxine, TSH=Thyroid stimulating hormone. *n (%) Table 3 presents data on knowledge and clinical practices related to LT3 use among 455 doctors. A majority (364, 80%) reported awareness of LT3 availability in India, with the highest awareness among endocrinologists (125, 99.21%), followed by physicians (190, 73.64%) and the ‘others’ category (28, 73.68%). Awareness was lower among gynaecologists and general practitioners (63.64% each). Regarding availability, 215 doctors (47.25%) believed LT3 is easily available, 103 (22.64%) said it is available with difficulty, 17 (3.74%) said very difficult, and 120 (26.37%) were unsure. Among endocrinologists, 90 (71.43%) found it easily available, while only 36.82% of physicians and 36.36% of gynaecologists agreed. LT3 use in clinical practice was reported by 240 doctors (52.75%), highest among endocrinologists (94, 74.60%), followed by physicians (118, 45.74%) and others (17, 44.74%). Only three gynaecologists (27.27%) and eight general practitioners (36.36%) had used it. Among prescribers, 89 (37.08%) used it in fewer than five patients, 83 (34.58%) in 5–10, 42 (17.50%) in 10–30, 15 (6.25%) in 30–100, and 11 (4.58%) in over 100 patients. Among endocrinologists, 5 (5.32%) reported using it in more than 100 patients, while only one physician (0.85%) did so. Once-daily dosing was the most common regimen (149 doctors, 62.08%). Among endocrinologists, 46 (48.94%) prescribed twice daily and 43 (45.74%) once daily. Most physicians (80, 67.80%) preferred once daily. All gynaecologists and nearly all in the ‘others’ group also prescribed LT3 once daily, indicating a general preference for simpler dosing outside endocrine specialties. Table 3Knowledge and practices related to liothyronine usage in their clinical practice among the doctors of different specialtiesTotal participants n=455Endocrinologists n=126Physicians n=258Gynaecologists n=11General practitioners n=22Others n=38Aware about its availability in India Yes364 (80%)125 (99.21%)190 (73.64)7 (63.64%)14 (63.64%)28 (73.68%)Perception about ease of its availability Easily215 (47.25%)90 (71.43%)95 (36.82%)4 (36.36%)9 (40.91%)17 (44.74%) With difficulty103 (22.64%)29 (23.02%)63 (24.42%)1 (9.09%)3 (13.64%)7 (18.42%) Very difficult17 (3.74%)3 (2.38%)13 (5.04%)-1 (4.55%)- Don’t know/not sure120 (26.37%)4 (3.17%)87 (33.72%)6 (54.55%)9 (40.91%)14 (36.84%)Used in practice Yes240 (52.75%)94 (74.60%)118 (45.74%)3 (27.27%)8 (36.36%)17 (44.74%)Used in approx. number of patients till date <589 (37.08%)45 (47.87%)34 (28.81%)1 (33.34%)3 (37.50%)6 (35.29%) 5–1083 (34.58%)18 (19.15%)58 (49.15%)2 (66.67%)1 (12.50%)4 (23.53%) 10–3042 (17.50%)16 (17.02%)20 (16.95%)-1 (12.50%)5 (29.41%) 30–10015 (6.25%)10 (10.64%)5 (4.24%)--- >10011 (4.58%)5 (5.32%)1 (0.85%)-3 (37.50%)2 (11.76%)Usual prescribed frequency of administration for LT3 Once a day149 (62.08%)43 (45.74%)80 (67.80%)3 (100%)7 (87.50%)16 (94.12%) Twice a day72 (30.00%)46 (48.94%)24 (20.34%)-1 (12.50%)1 (5.88%) None of the above19 (7.92%)5 (5.32%)14 (11.86%)---*LT4=Levothyroxine. *n (%) Knowledge and practices related to liothyronine usage in their clinical practice among the doctors of different specialties *LT4=Levothyroxine. *n (%) Table 4 presents the most common reason or scenario cited by participating doctors for prescribing LT3 in their clinical practice. Among the 240 doctors who reported using LT3 in their clinical practice, the most commonly cited reason or scenario for its use was hypothyroid emergencies or myxoedema coma by 97 (40.42%) doctors. This was followed by 54 (22.50%) doctors who answered rapid control of hypothyroidism as the most common scenario or reason to use LT3. Forty-two (17.50%) doctors cited using in patients had persisting symptoms despite normal TSH levels while on LT4 monotherapy as most common reason, while 33 (13.75%) doctors reported using LT3 for refractory hypothyroidism, defined as elevated TSH despite a LT4 dose of 1.9 μg/kg/day or unexpectedly high doses of LT4 as most common scenario to consider additional LT3. Lastly, 14 doctors (5.83%) indicated peri-operative use of LT3 as their most common reason for prescribing it. These findings reflect the diverse clinical scenarios in which LT3 is considered, with a clear preference for its use in hypothyroid emergency or where rapid control of TSH is desired. Table 4Reasons for prescribing the liothyronine by doctors of different specialties (n=240)Parametersn (%)Most important scenario/reason for using LT3 in clinical practice• Hypothyroid emergency/myxoedema coma97 (40.42%)• Rapid control of hypothyroidism54 (22.50%)• Persisting symptoms with normal TSH on LT442 (17.50%)Refractory hypothyroidism (elevated TSH in spite of 1.9 µg/kg/day of LT4 or unexpected high dose of LT4)33 (13.75%)• Peri-operative use14 (5.83%)*LT4=Levothyroxine, TSH=Thyroid stimulating hormone, LT3=Liothyronine. *n (%) Reasons for prescribing the liothyronine by doctors of different specialties (n=240) *LT4=Levothyroxine, TSH=Thyroid stimulating hormone, LT3=Liothyronine. *n (%) Table 5 summarizes the reasons mentioned by participating doctors for not prescribing LT3. The most frequently cited reason was cost, reported by 107 (23.52%) doctors, closely followed by availability issues, reported by 104 (22.86%) doctors. A substantial proportion of 59 (12.97%) doctors indicated that they did not perceive any additional benefit from using LT3 over existing therapies. Additionally, 46 (10.11%) doctors admitted to having no experience or lacking confidence in prescribing LT3. Further exploring specific barriers, cost emerged as a substantial hindrance, with 130 (28.57%) doctors reporting it as a limiting factor ‘in most cases’ and 140 (30.77%) saying that it is ‘often’ the issue. Similarly, availability was reported as a major hindrance ‘in most cases’, by 109 (23.96%) doctors and 112 (24.62%) reported availability as ‘often’ the issue. These findings suggest that both economic and logistical challenges significantly impact the adoption of LT3 therapy in routine clinical practice. Table 5Reasons for non-prescribing liothyronine by doctors of different specialties (n=455)Parametersn (%)Reasons for its no/limited use in practice Cost107 (23.52%) Availability104 (22.86%) Did not felt any additional benefit for use59 (12.97%) No experience/not confident about the use46 (10.11%) Not sure about efficacy and safety27 (5.93%) Patient acceptance8 (1.76%) None of the above20 (4.40%) Not relevant for me84 (18.46%)Cost being hindrance for using LT3 in your practice In most cases130 (28.57%) Often140 (30.77%) Rare64 (14.07%) Not relevant for me121 (26.59%)Availability being hindrance for using LT3 in your practice In most cases109 (23.96%) Often112 (24.62%) Rare100 (21.98%) Not relevant for me134 (29.45%)*LT4=Levothyroxine, TSH=Thyroid Stimulating Hormone, LT3=Liothyronine. *n (%) Reasons for non-prescribing liothyronine by doctors of different specialties (n=455) *LT4=Levothyroxine, TSH=Thyroid Stimulating Hormone, LT3=Liothyronine. *n (%) Responses related to preference for future education and learning about LT3 by participating doctors are shown in Table 6. A significant majority of doctors surveyed expressed a willingness to enhance their clinical knowledge about LT3, with 338 (74.29%) participants indicating a positive preference towards learning from experts. Regarding their preferred mode of learning, conferences emerged as the most favoured option, selected by 179 doctors (39.34%), followed by reading material or articles by 90 doctors (19.78%), followed by webinars by 43 (9.45%) participants, and round table discussion by 26 (5.71%) participants. These findings highlight a strong interest among healthcare professionals in improving their understanding of LT3, with a clear inclination towards self-paced, literature-based learning formats as well as through professional conferences. Table 6Preference for future education and learning regarding liothyronine among doctors who participated in the study (n=455)Parametersn (%)Preference for enhancing clinical knowledge regarding LT3 from the experts Yes338 (74.29%) No50 (10.99%) Not relevant for me67 (14.73%)Best medium that you would like to learn about LT3 Conference179 (39.34%) Reading material/article90 (19.78%) Webinar43 (9.45%) Round table discussion26 (5.71%) Not relevant for me117 (25.71%)*LT3=Liothyronine. *n (%) Preference for future education and learning regarding liothyronine among doctors who participated in the study (n=455) *LT3=Liothyronine. *n (%) DISCUSSION This study provided valuable insights into the clinical perceptions and usage patterns of LT3 among doctors in India. This is the first such Indian study which has reported perceptions related to and clinical usage of LT3 by large number of doctors practising in different states and set up and belonging to different clinical specialities. This study included a diverse group of participants, mainly physicians and endocrinologists, with varying levels of clinical experience, offering a comprehensive perspective on hypothyroidism management in India. The demographic diversity—across gender, specialty, and experience—highlighted differing treatment strategies. Participants practiced in varied clinical settings, including metro and district cities, private hospitals, clinics, and medical colleges. Patient volume influenced clinical decisions. Additionally, a related study in New Delhi revealed poor awareness and common misconceptions about hypothyroidism, despite high adherence (90.4%) to T4 therapy.[13] A recent systematic review of clinical practice guidelines found that LT4 monotherapy remains the standard treatment for hypothyroidism, with LT4 + LT3 combination therapy recommended only in select, experimental cases.[14] In line with this, our study confirmed that while most patients on LT4 become asymptomatic after dose optimization, a notable minority continues to experience symptoms, emphasizing the need for personalized treatment approaches. Approximately 5%–10% of patients on LT4 report persistent symptoms such as fatigue, depression, and cognitive impairment despite normal biochemical levels, impacting their quality of life.[2] A 2019 study showed that patients with severe primary hypothyroidism (TSH ≥40 μIU/ml) had more symptoms and higher lipid levels than those with milder forms. After 12 weeks of LT4 therapy, significant improvements were observed in weight, haemoglobin, and lipid profile, although some symptoms like fatigue (10%) and poor memory (8%) remained.[15] There is a growing willingness among physicians to consider combination therapy in specific cases, but further research is needed to evaluate the safety and efficacy of alternatives to LT4.[16] The role of combination therapy with LT4 and LT3 remains uncertain pending large randomized controlled trials in targeted populations.[17] However, a trial may be considered for selected patients with persistent symptoms, provided that it is overseen by experienced clinicians with clear communication, careful monitoring, and informed patient consent.[17] The Joint British Thyroid Association/Society for Endocrinology consensus acknowledges that persistent symptoms are common and supports a cautious trial of combination therapy in patients with confirmed overt hypothyroidism and unresolved symptoms. Long-term LT3 use should be limited to those with sustained benefits, with regular TSH monitoring to prevent iatrogenic hyperthyroidism. Overprescription, especially in subclinical cases, should be avoided, and deprescribing considered when appropriate. Treatment decisions should be collaborative, ensuring that LT4 is optimized and other causes ruled out. LT3, available as a sodium salt, is rapidly absorbed in the duodenum.[18] More than 20 RCTs have shown LT4 + LT3 combination therapy to be safe and effective, supported by retrospective population-level studies.[19] Innovations, like slow-release LT3, tissue-specific T3 signalling, and thyroid organoids, show promise, though currently available LT3 can still be safely used to improve quality of life in selected hypothyroid patients.[19] Originally FDA-approved in 1956, LT3 was introduced in India by Abbott in 2022, though it faces availability and cost challenges.[20] The data regarding use of LT3 in practice in India is very scarce. The majority of respondents in India were aware of LT3’s availability, with nearly half reporting easy access. The reasons for prescribing LT3 primarily centred on hypothyroid emergencies, rapid control of hypothyroidism, and persisting symptoms despite normal TSH on LT4.[21] The barriers to prescribing LT3 were mainly concerns over cost, availability, and lack of experience, with cost being the most frequently cited issue. These factors, along with a perceived lack of additional benefit, suggest that practical and logistical challenges limit the broader adoption of LT3 in clinical practice. However, the prolonged use of LT3 poses challenges as it requires multiple daily doses, which can affect patient adherence. Additionally, LT3 is significantly more expensive than LT4, leading to variability in patient access. As a result, careful selection of patients who may benefit from combined LT3 and LT4 therapy is essential.[222] Healthcare professionals are keen on improving their knowledge of LT3, with reading materials being the most preferred method. Conferences and webinars are also preferred, indicating a need for educational resources to enhance confidence and clinical decision-making. As India continues to address hypothyroidism, increasing awareness, targeted screening, and effective management will be crucial, along with tailoring treatment approaches to individual patient needs.[10] The authors of a consensus document on evidence-based use of LT4/LT3 combinations in treating hypothyroidism advocated for a well-designed, adequately powered clinical trials on combination therapy, supported by additional physiological and translational data to address patient and physician interest in improving thyroid hormone therapy.[23] The findings of our study may help in generate evidence-based guidelines to enhance patient care in India. Strengths and limitations The study involved over 450 healthcare professionals from India, including family physicians, obstetricians, paediatricians, surgeons, and endocrinologists. A well-designed questionnaire was used, ensuring reliability of the questions and methodology. The study used a mix of purposive and convenience sampling methods, ensuring cost-effectiveness, targeted insights and a larger diverse sample. The study utilized an online structured questionnaire, involving only doctors actively involved in primary hypothyroidism treatment, for easy data collection and consistency of responses. One hundred per cent response was ensured to all the questions from doctors whose responses were submitted and analysed. The study has several limitations, including selection bias due to voluntary participation, potential response bias from self-reporting to socially desirable responses, and the cross-sectional design, which limits causal inferences and trend analysis over time. Additionally, targeting doctors attending a CME programme may not fully represent all healthcare providers in India, affecting the generalizability of the findings. CONCLUSION This study highlights the limited but evolving use of synthetic LT3 for primary hypothyroidism in India, mainly for patients with persistent symptoms despite normal TSH on LT4 therapy. Its adoption is constrained by safety concerns, monitoring difficulties, cost, limited availability, and low awareness, especially among general practitioners. The absence of India-specific guidelines further hampers its use. To promote appropriate LT3 use, clinician education, updated local protocols, better accessibility, and India-focused research are essential for more informed, patient-centred care. Authors contribution SA, DK, and SC conceived the presented research idea. LG, UG, MTS, and SS were involved in research conduction and data acquisition. LG, NP, and MS performed the computations and manuscript writing. All authors contributed to the article and approved the submitted version. Conflicts of interest There are no conflicts of interest. Use of artificial intelligence All authors confirm that we have not used any artificial intelligence assisted technologies in any aspect of the creation and writing of the manuscript. Data availability Datasets generated during the current study are available from the corresponding author on reasonable request.